We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

821 hedge funds and large institutions have $59.2B invested in Alnylam Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 224 funds opening new positions, 282 increasing their positions, 223 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

357% more first-time investments, than exits

New positions opened: 224 | Existing positions closed: 49

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

37% more capital invested

Capital invested by funds: $43.1B → $59.2B (+$16.1B)

26% more repeat investments, than reductions

Existing positions increased: 282 | Existing positions reduced: 223

26% more funds holding

Funds holding: 653 → 821 (+168)

2.24% less ownership

Funds ownership: 101.33% → 99.09% (-2.2%)

13% less call options, than puts

Call options by funds: $562M | Put options by funds: $649M

Holders
821
Holders Change
+168
Holders Change %
+25.73%
% of All Funds
10.77%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.17%
New
224
Increased
282
Reduced
223
Closed
49
Calls
$562M
Puts
$649M
Net Calls
-$86.5M
Net Calls Change
-$71M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$1.01B
2
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$483M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$391M
4
Jane Street
Jane Street
New York
+$381M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$330M

Top Sellers

Rank Fund Capital Flow
1
RP
Regeneron Pharmaceuticals
New York
-$1.24B
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$858M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$548M
4
Winslow Capital Management
Winslow Capital Management
Minnesota
-$479M
5
Dodge & Cox
Dodge & Cox
California
-$357M
Name Holding Trade Value Shares
Change 		Change in
Stake
CH
751
Cromwell Holdings
Wyoming
$9.12K – – –
DWM
752
Dogwood Wealth Management
Kansas
$9.12K – – –
TH
753
TCTC Holdings
Texas
$8.66K – – –
EPW
754
Evergreen Private Wealth
Colorado
$7.75K – – –
CTC
755
Cetera Trust Company
Minnesota
$7.3K – – –
VWWMG
756
Vermillion & White Wealth Management Group
Pennsylvania
$7.3K +$6.51K +16 New
SAM
757
Sherman Asset Management
California
$6.84K – – –
STB
758
S&T Bank
Pennsylvania
$6.84K – – –
SS
759
Sunbelt Securities
Texas
$6.84K – – –
GA
760
Guerra Advisors
Florida
$6.84K +$6.11K +15 New
MG
761
Mather Group
Illinois
$6.55K +$5.7K +14 New
TCOV
762
Trust Company of Vermont
Vermont
$6.38K – – –
MAM
763
Marquette Asset Management
Minnesota
$6.38K +$5.7K +14 New
VNA
764
Valley National Advisers
Pennsylvania
$6K +$6.11K +15 New
CWIG
765
Chung Wu Investment Group
Texas
$5.93K – – –
M
766
MOTCO
Texas
$5.93K +$5.29K +13 New
NS
767
NBC Securities
Alabama
$5.47K – – –
UB
768
UMB Bank
Missouri
$5.47K +$1.63K +4 +50%
MCM
769
Manchester Capital Management
Vermont
$5.47K +$3.67K +9 +300%
ACM
770
Accent Capital Management
Ohio
$5.47K +$4.89K +12 New
JFGIW
771
Johnson Financial Group Inc (Wisconsin)
Wisconsin
$5.47K +$4.89K +12 New
HFS
772
Hughes Financial Services
Virginia
$5.3K – – –
AIC
773
Archer Investment Corporation
Indiana
$4.56K – – –
MSFP
774
Mark Sheptoff Financial Planning
Connecticut
$4.56K – – –
TWM
775
Tripletail Wealth Management
Florida
$4.54K +$4.07K +10 New
29 30
31
32 33

ALNY Hedge Fund Activity: Q3 2025 in Review

821 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2025, worth a combined $59.2B — up 37% from $43.1B a quarter earlier.

Buyers outnumbered sellers: 224 funds opened new ALNY positions and 49 closed out — a net gain of 175 holders — while 282 added to existing stakes and 223 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $1.01B. The largest seller was Regeneron Pharmaceuticals, cutting an estimated $1.24B.

  • 821 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2025, up from 653 in Q2 2025.
  • Funds reported $59.2B of Alnylam Pharmaceuticals stock for Q3 2025, up 37% quarter-over-quarter.
  • 224 funds opened new Alnylam Pharmaceuticals positions in Q3 2025 and 49 closed out, a net change of +175 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q3 2025 was JP Morgan Chase, an estimated $1.01B added.
  • The largest Alnylam Pharmaceuticals seller in Q3 2025 was Regeneron Pharmaceuticals, an estimated $1.24B sold.

Based on aggregated 13F filings for Q3 2025.